Efflux pump inhibitors aim to overcome multidrug resistance, with third-generation inhibitors like elacridar showing promise despite toxicity concerns. Nanoparticles improve drug delivery to the brain, with liposome-based NPs being common. Despite advancements, challenges like protein corona formation and administration methods affect efficacy. Optimizing nanoparticle features is crucial for effective brain tumor treatments.